Jazz Pharmaceuticals Plc Stock Rating Lowered by R. F. Lafferty (JAZZ)
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) was downgraded by investment analysts at R. F. Lafferty from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, Analyst Ratings Network reports. They currently have a $140.00 price objective on the stock. R. F. Lafferty’s target price would suggest a potential downside of 4.66% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Brean Capital raised their price target on shares of Jazz Pharmaceuticals Plc to $171.00 in a research note to investors on Friday, December 20th. Separately, analysts at Goldman Sachs Group Inc. downgraded shares of Jazz Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research note to investors on Monday, December 16th. They now have a $123.00 price target on the stock, up previously from $105.00. Finally, analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $110.00 to $130.00 in a research note to investors on Friday, December 6th. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $111.11.
Shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 2.65% during mid-day trading on Tuesday, hitting $142.948. 236,123 shares of the company’s stock traded hands. Jazz Pharmaceuticals Plc has a one year low of $50.76 and a one year high of $148.14. The stock’s 50-day moving average is $121.7 and its 200-day moving average is $94.32. The company has a market cap of $8.261 billion and a price-to-earnings ratio of 24.96.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last released its earnings data on Tuesday, November 5th. The company reported $1.78 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.67 by $0.11. The company had revenue of $232.20 million for the quarter, compared to the consensus estimate of $227.38 million. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 32.3% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.